Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

63.28
+0.04000.06%
Volume:13.87K
Turnover:872.73K
Market Cap:7.50B
PE:24.72
High:63.28
Open:63.05
Low:62.68
Close:63.24
52wk High:82.22
52wk Low:47.50
Shares:118.47M
Float Shares:116.00M
Volume Ratio:2.99
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.56
EPS(LYR):2.56
ROE:153.59%
ROA:22.24%
PB:153.58
PE(LYR):24.72

Loading ...

Halozyme Signs Global License Agreement With Merus for Subcutaneous Petosemtamab

Reuters
·
Nov 17, 2025

Merus Nv - to Make Upfront and Milestone Payments to Halozyme

THOMSON REUTERS
·
Nov 17, 2025

Merus Nv: Halozyme Will Also Be Entitled to up to Low-Mid Single Digit Royalties on Net Sales of Petosemtamab

THOMSON REUTERS
·
Nov 17, 2025

Merus Nv - Licenses Halozyme's Enhanze for Petosemtamab

THOMSON REUTERS
·
Nov 17, 2025

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

THOMSON REUTERS
·
Nov 17, 2025

Halozyme Therapeutics Director Bernadette Connaughton Reports Disposal of Common Shares

Reuters
·
Nov 13, 2025

Halozyme Therapeutics (HALO): Exploring Valuation Following Strong Q3 Results and Upgraded Guidance

Simply Wall St.
·
Nov 13, 2025

BUZZ-Halozyme Therapeutics down after $1.3 bln convertible bonds sale

Reuters
·
Nov 08, 2025

BRIEF-FDA Approved DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma

Reuters
·
Nov 07, 2025

Halozyme: JNJ gets FDA approval for new indication of DARZALEX Faspro

TIPRANKS
·
Nov 07, 2025

FDA Approved Darzalex Faspro® for Adult Patients With High-Risk Smoldering Multiple Myeloma

THOMSON REUTERS
·
Nov 07, 2025

Halozyme Therapeutics Prices $1.3 Billion Private Debt Offering

MT Newswires Live
·
Nov 07, 2025

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes Due 2031 and $650 Million of Convertible Senior Notes Due 2032

THOMSON REUTERS
·
Nov 07, 2025

Halozyme Therapeutics Announces $1.3 Billion Convertible Senior Notes Offering

Reuters
·
Nov 06, 2025

Stock Track | Halozyme Therapeutics Soars 5.54% on Strong Q3 Results and Positive Analyst Actions

Stock Track
·
Nov 04, 2025

Halozyme Therapeutics Inc : Benchmark Cuts Target Price to $75

THOMSON REUTERS
·
Nov 04, 2025

Halozyme Therapeutics Is Maintained at Market Outperform by Citizens

Dow Jones
·
Nov 04, 2025

Halozyme Therapeutics Inc : Leerink Partners Raises Target Price to $72 From $70

THOMSON REUTERS
·
Nov 04, 2025

Halozyme Raises FY Outlook; Finance Chief to Depart by March

Dow Jones
·
Nov 04, 2025

Halozyme Therapeutics Q3 Adjusted EPS USD 1.72 Vs. IBES Estimate USD 1.63

Reuters
·
Nov 04, 2025